What medication is recommended for short‑term treatment of insomnia?

Medication for Short-Term Treatment of Insomnia

For short-term insomnia treatment, non-benzodiazepine receptor agonists (Z-drugs) such as zolpidem, eszopiclone, or zaleplon are recommended as first-line pharmacotherapy, with the critical caveat that Cognitive Behavioral Therapy for Insomnia (CBT-I) should be initiated concurrently or beforehand, as it provides superior long-term outcomes. 1

First-Line Treatment Approach

• CBT-I must be initiated before or alongside any medication because it demonstrates superior long-term efficacy with sustained benefits after discontinuation, whereas medication effects cease when stopped. 2, 1
• CBT-I includes stimulus control (use bed only for sleep, leave after ~20 minutes if unable to sleep), sleep restriction (limit time-in-bed to actual sleep time + 30 minutes), cognitive restructuring, relaxation techniques, and sleep hygiene education. 1
• Sleep hygiene education alone is insufficient as monotherapy but should supplement other CBT-I components. 1

First-Line Pharmacologic Options (When CBT-I Alone Is Insufficient)

For Sleep-Onset Insomnia

• Zolpidem 10 mg (5 mg if age ≥65 years) shortens sleep-onset latency by ~25 minutes and increases total sleep time by ~29 minutes; take within 30 minutes of bedtime with ≥7 hours remaining before awakening. 1
• Zaleplon 10 mg (5 mg if age ≥65 years) has an ultrashort half-life (~1 hour), providing rapid sleep initiation with minimal next-day sedation; suitable for middle-of-night dosing when ≥4 hours remain before awakening. 1, 3
• Ramelteon 8 mg is a melatonin-receptor agonist with no abuse potential, no DEA scheduling, and no withdrawal symptoms, making it appropriate for patients with substance use history. 1

For Sleep-Maintenance Insomnia

• Low-dose doxepin 3–6 mg reduces wake after sleep onset by 22–23 minutes via selective H₁-histamine antagonism, with minimal anticholinergic effects at hypnotic doses and no abuse potential. 1
• Suvorexant 10 mg (orexin-receptor antagonist) reduces wake after sleep onset by 16–28 minutes and carries lower risk of cognitive and psychomotor impairment than benzodiazepine-type agents. 1

For Combined Sleep-Onset and Maintenance Insomnia

• Eszopiclone 2–3 mg (1 mg if age ≥65 years or hepatic impairment) increases total sleep time by 28–57 minutes and produces moderate-to-large improvements in subjective sleep quality. 1

Duration and Safety Considerations

• FDA labeling limits hypnotic use to ≤4 weeks for acute insomnia; evidence beyond this duration is insufficient. 1
• Benzodiazepines (eszopiclone, zaleplon, zolpidem) and daridorexant can be used for short-term treatment (≤4 weeks), with longer-term use considered in some cases after weighing advantages and disadvantages. 4
• Orexin receptor antagonists can be used for periods up to 3 months or longer in selected cases. 4
• Use the lowest effective dose for the shortest duration possible, and reassess after 1–2 weeks to evaluate efficacy on sleep latency, total sleep time, nocturnal awakenings, and daytime functioning. 1

Critical Safety Warnings

• All benzodiazepine-receptor agonists carry FDA warnings for complex sleep behaviors (sleep-driving, sleep-walking, sleep-eating); discontinue immediately if these occur. 2, 1
• Combining multiple sedating agents markedly increases risk of respiratory depression, cognitive impairment, falls, and fractures. 1
• Age-adjusted dosing is mandatory for older adults (e.g., zolpidem ≤5 mg, eszopiclone ≤2 mg) to reduce fall risk. 1

Medications Explicitly NOT Recommended for Short-Term Insomnia

• Trazodone yields only ~10-minute reduction in sleep latency with no improvement in subjective sleep quality; adverse events occur in ~75% of older adults, and harms outweigh benefits. 2, 1
• Over-the-counter antihistamines (diphenhydramine, doxylamine) lack efficacy data, cause strong anticholinergic effects (confusion, urinary retention, falls, delirium), and tolerance develops within 3–4 days. 2, 1, 4
• Traditional benzodiazepines (lorazepam, clonazepam, diazepam) have long half-lives causing drug accumulation, prolonged daytime sedation, higher fall and cognitive-impairment risk, and associations with dementia and fractures. 2, 1
• Antipsychotics (quetiapine, olanzapine) have weak evidence for insomnia benefit and significant risks including weight gain, metabolic syndrome, extrapyramidal symptoms, and increased mortality in elderly with dementia. 2, 1, 4
• Antihistaminergic drugs, fast-release melatonin, ramelteon, and phytotherapeutics are not recommended for insomnia treatment. 4

Common Pitfalls to Avoid

• Initiating pharmacotherapy without first implementing CBT-I violates strong guideline recommendations and yields less durable benefit. 1
• Continuing hypnotics beyond 4 weeks without periodic reassessment contradicts FDA labeling and guideline advice. 1
• Using adult dosing in elderly patients increases fall risk; age-adjusted dosing is essential. 1
• Prescribing agents without matching their pharmacologic profile to the insomnia phenotype (e.g., using zaleplon for maintenance rather than onset). 1